Back to Results

A Phase 1a/1b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PY159 as a Single Agent and In Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

Study category: Cancer

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Eligibility

patients enrolled to Part B must express TREM-1 by IHC.

Type of Study

Treatment

Location

University of Colorado Hospital

Principal Investigator
Erin Schenk,  MD, PhD

Erin Schenk, MD, PhD

Study ID

Protocol Number: 20-2818

More information available at ClinicalTrials.gov: NCT04682431

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers